| Vol. 13.41 – 18 October, 2022 |
| |
|
|
| Scientists explored the contribution of energy metabolism to microglial function in Alzheimer’s disease (AD) and demonstrated that hexokinase 2 was elevated in microglia from an AD mouse model and patients. [Nature Metabolism] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers presented that seizure threshold 2 (SZT2), a protein required for mTORC1 downregulation upon nutrient deprivation, was critical for HSC homeostasis, where ablation of SZT2 in HSCs decreased the reserve and impaired the repopulating capacity. [Journal of Clinical Investigation] |
|
|
|
| Using genetic Hsf1 deletion and a direct heat shock transcription factor 1 (HSF1) small molecule inhibitor, scientists showed that HSF1 was specifically required for the maintenance of AML, while sparing steady-state and stressed hematopoiesis. [Nature Communications] |
|
|
|
| Investigators presented a novel and essential role for the caspase-10-P13-tBID axis in erythroid terminal differentiation. [Cell Death & Differentiation] |
|
|
|
| Scientists identified increased expression of a c-Mpl alternative splicing isoform, c-Mpl-del, in acute megakaryocytic leukemia patients. [Cell Death & Disease] |
|
|
|
| Scientists demonstrated that loss of DEAD-Box Helicase 41 (DDX41) function impaired efficient RNA splicing, resulting in DNA replication stress with excess R-loop formation in hematopoietic cells. [Leukemia] |
| |
|
|
| The primary analysis of this Blood and Marrow Transplant Clinical Trials Network study showed the survival advantage associated with allogeneic hematopoietic cell transplantation in older adults with myelodysplastic syndromes did not come at the cost of worse quality of life. [American Journal of Hematology] |
|
|
|
| Researchers evaluated the impact of the time interval between end of induction and autologous hematopoietic transplantation on progression-free survival and overall survival in multiple myeloma patients. [Bone Marrow Transplantation] |
|
|
|
| Researchers performed a retrospective cohort study of Philadelphia chromosome positive acute lymphoblastic leukemia patients who received tyrosine kinase inhibitor therapy pre- and post-allogeneic HSC transplant from April 2007 to November 2019. [International Journal of Cancer] |
|
|
|
|
| The authors provide a comprehensive summary of the recent challenges and developments in allogeneic HSC transplantation as a curative treatment for myelodysplastic syndromes, primarily affecting older persons. [American Journal of Hematology] |
|
|
|
| Investigators discuss the methods of transplantation of genetically edited human HSCs being explored and describe progress made so far with several primary immunodeficiencies. [Molecular Diagnosis & Therapy] |
|
|
|
|
| Adaptive Biotechnologies Corporation announced a partnership with Epic to integrate the clonoSEQ® Assay into Epic’s comprehensive electronic medical record system. For patients with blood cancers, clonoSEQ is the only FDA-cleared test that can monitor minimal residual disease. [Adaptive Biotechnologies Corporation] |
|
|
|
| Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform which provides potential as a treatment for blood cancers. [Gilead Sciences, Inc.] |
|
|
|
|
| November 7 – 9, 2022 Singapore, Singapore |
|
|
|
|
|
| Karolinska Institutet – Stockholms, Sweden |
|
|
|
| University of Colorado Denver – Aurora, Colorado, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Blood Centre of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| CancerCare Manitoba Research Institute – Winnipeg, Manitoba, Canada |
|
|
|
|